|
Market Cap (24-Jun) $24,941,990 (1,259th) |
Close (30-Jun) $0.080 |
Volume (30-Jun) 244,049 |
Shortsold (15-Jan) 38,875 (0.01%) (540th) |
|
52w High $0.260 |
52w Low $0.059 |
P/E - |
EPS -0.02 |
NSB released this announcement to the ASX on 30 August 2022, 8:02. The announcement is marked as price sensitive, and is 61 page(s) in length and 1.85MB in size.
You can view all announcements from NSB and see how they appear on a price chart on the announcements page.
At the date of this announcement, NSB was 0.012% short sold according to ASIC data. It was ranked the 617th most shorted stock on the ASX. It is now ranked as the 540th most shorted stock on the ASX with 0.012% of total shares short sold as of the latest reported data (15 January 2026).
| Other Recent Announcements from NSB | |
|---|---|
| Change of Director's Interest Notice - Rennie | 7 June 2023, 8:22 |
| Change of Director's Interest Notice - Uvarov | 25 May 2023, 15:30 |
| Change of Director's Interest Notice - Rennie | 25 May 2023, 15:07 |
| 2022 Annual Report and Appendix 4E | 30 August 2022, 8:02 |
| R&D Tax Incentive Refund Received | 17 August 2022, 8:12 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 29 July 2022, 18:05 |
| HREC Submission for Phase I Clinical Trial | 12 July 2022, 9:50 |
You must be logged in to post a reply.
NeuroScientific Biopharmaceuticals 